Skip to main content
SpringerLink
Log in

The Development of Oral UFT with and without Leucovorin

  • Chapter
Fluoropyrimidines in Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 200 Accesses

Abstract

The fluoropyrimidines are among the most active classes of anticancer agents used in the chemotherapy of colorectal cancer. More than 40 yr after its introduction, intravenous 5- fluorouracil (IV 5-FU) therapy remains a fundamental treatment for this disease. Results, however, are moderate at best and IV 5-FU is typically associated with significant toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bjerkeset T, Fjosne HE. Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. Oncology 1986; 43: 212–215.

    Article  PubMed  CAS  Google Scholar 

  2. Palmeri S, et al. Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study. Br J Cancer 1990; 61: 475–478.

    Article  PubMed  CAS  Google Scholar 

  3. Ron IG, Lotan A, Inbar MJ, Chaitchik S. Advanced colorectal carcinoma: redefining the role of oral ftorafur. Anticancer Drugs 1996; 7: 649–654.

    Article  PubMed  CAS  Google Scholar 

  4. Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978; 69: 763–772.

    PubMed  Google Scholar 

  5. Rustum YM. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology 1997;54 Suppl 1: 7–11.

    Google Scholar 

  6. Taguchi T. Experience with UFT in Japan. Oncology (Huntingt) 1997; 11: 30–34.

    CAS  Google Scholar 

  7. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22: 333–338.

    Article  PubMed  CAS  Google Scholar 

  8. Malik ST, et al. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1990; 62: 1023–1025.

    Article  PubMed  CAS  Google Scholar 

  9. Sanchiz F, Millia A. Tegafur (UFT) in advanced colorectal cancer, a phase II study. Anticancer Res 1988; 8: 1122.

    Google Scholar 

  10. Nogue Aliguer M, & Saigi Grau E. Tratamiento prologado con UFT y bajas dosis de leucovorin oral: estudio fase I. Oncologia 1992; 15: 114–116.

    Google Scholar 

  11. Camps C, Berrocal A, Vicent JM, et al. Phase I-II trial of Tegafur-Uracil and low dose leucovorin in advanced colorectal carcinoma. Ann Oncol 1994; 5: 56.

    Google Scholar 

  12. Gonzalez-Baron M, et al. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 1995; 31A: 2215–2219.

    Article  Google Scholar 

  13. Feliu J, Gonzalez-Baron M, Ordonez A, & et al. Treatment of advanced colorectal cancer in the elderly with UFT-leucovorin: an active and few toxic scheme. Ann Oncol 1996;(Suppl 5 ): 44.

    Google Scholar 

  14. Abad A, et al. A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group). Oncology (Huntingt) 1997; 11: 53–57.

    CAS  Google Scholar 

  15. Pazdur R, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 2296–2300

    PubMed  CAS  Google Scholar 

  16. Sanchiz F, Milla A. Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer. Jpn J Clin Oncol 1994; 24: 322–326.

    PubMed  CAS  Google Scholar 

  17. Pazdur R. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. Oncology (Huntingt) 1997; 11: 35–39.

    CAS  Google Scholar 

  18. Straw JA, Stapary D, Wynn WT. Pharmacokinetics of the diasteroisomers of leucovoriin after intraavenous an dorai administration to normal subjects. Cancer Res 1994; 44: 3114–3119.

    Google Scholar 

  19. Douillard JY. A phase I study of oral uracil/tegafur (UFT) plus leukovorin (LV) combined with oxaliplatin in patients with metastatic colorectal cancer. 1999.

    Google Scholar 

  20. Douillard JY, Cunningham D, Roth AD, et al. A randomized phase III trial comparing irinotecan (IRI) + 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT). Proc Am Soc Clin Oncol 1999; 18: 233a.

    Google Scholar 

  21. Carmichael J, Popiela T, Radstone D, et al. Randomised comparative study of ORZEL ((oral uracil/tegafur UFT plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 264a.

    Google Scholar 

  22. Borner M, Schoeffski P, de Wit R, et al. A randomised crossover trial comparing UFT + leucovorin (LV) and fluorouracil (FU) + LV for patient preference and pharmacokinetics in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 191a.

    Google Scholar 

  23. Meropol NJ, Creaven PJ, Petrelli NJ. Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Semin Oncol 1995; 22: 509–524.

    PubMed  CAS  Google Scholar 

  24. Hill M, Twelves C, Cunningham D. A phase I/II study of oral uracil/tegafur (UFT) plus… or metastatic colorectal cancer (CRC). 2000.

    Google Scholar 

  25. Gravalos C, Garcia-Alfonso P, Castellanos D. Phase I trial of escalating doses of irinotecan (CPT-11) in combination with UFT/folinic acid (FA) in patients with advanced colorectal cancer (CRC). Ann Oncol 2000;l 1(Suppl 4 ): 46.

    Google Scholar 

  26. Escudero P, Vicente A, Herrero et al. Phase 1–11 trial of irinotecan (CPT-11) over a short IV weekly infusion combined with a fixed does of UFT in second line advanced colorectal carcinoma (ACRC). ASCO. 2000.

    Google Scholar 

  27. Giacchetti S, Zidani R, Perpoint B, et al. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 1997; 16: 229a.

    Google Scholar 

  28. Bleiberg H. Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 1998;77 Suppl 4: 1–3.

    Google Scholar 

  29. Garcia-Giron C, Feliu J, Vicent JM. Phase II trial of oxaliplatin-UFT-leucovorin (OXA-UFT-LV) combination in first line treatment of advanced colorectal cancer (ACC). n/a. 2000.

    Google Scholar 

  30. Pfeiffer P, Jakobsen A. Concurrent UFT/L-leukovorin and high-dose radiotherapy (60 Gy) in patients with locally advanced rectal cancer (LARC): a phase I/II trial. 2000.

    Google Scholar 

  31. Hoff PM, et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer In Process Citation]. J Clin Oncol 2000; 18: 3529–3534.

    PubMed  CAS  Google Scholar 

  32. Janjan NA, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the MD Anderson Cancer Center experience. Int J Radias Oncol Biol Phys. 1999; 44: 1027–1038.

    Article  CAS  Google Scholar 

  33. Pazdur R, Doulliard J-Y, Skillings J, et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 263a.

    Google Scholar 

Download references

Authors
  1. Geert H. Blijham MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Roswell Park Cancer Institute, Buffalo, NY, USA

    Youcef M. Rustum

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Blijham, G.H. (2003). The Development of Oral UFT with and without Leucovorin. In: Rustum, Y.M. (eds) Fluoropyrimidines in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-337-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-337-8_17

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-274-2

  • Online ISBN: 978-1-59259-337-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation